AzTrials
AzTrials

HIV InfectionsPhase 1NCT01549509

Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda

A Phase 1 study testing VRC-HIVADV014-00-VP Vaccine in people with HIV Infections, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in Uganda.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The RV 156A clinical trial is evaluating an experimental HIV vaccine in people who are not infected with HIV. Participants in that study are randomly assigned to receive either the HIV vaccine or placebo. This study will enroll people who are participating in the RV 156 study. Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
HIV Infections
What is being tested?
VRC-HIVADV014-00-VP Vaccine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
18 participants
Where
1 siteUganda
Study dates
Apr 2007to Oct 2009
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • 18 to 40 years old at the time of RV 156 enrollment
  • Available for follow-up for the duration of the study (13 months)
  • Satisfactory completion of an Assessment of Understanding prior to enrollment, defined as 90% correct with three opportunities to take the test
  • Able and willing to sign the informed consent form
  • Willing to receive HIV counseling and testing in accordance with Ugandan Ministry of Health guidelines
  • Willing to not engage in high-risk behavior for HIV infection during the study as defined by the protocol and amenable to risk-reduction counseling and discussion of HIV infection risks
Show all 24Show fewer
  • In good general health
  • Physical examination and laboratory results without clinically significant findings within 45 days prior to rAd5 boost injection
  • Have participated in RV 156 and received all three required vaccinations
  • Laboratory Criteria within 45 days prior to enrollment:
  • Hemoglobin greater than 11.0 g/dL for women and 12.5 g/dL for men or accompanied by site physician approval and above the site's lower limit of normal (LLN) range
  • White blood cell count (WBC) of 3,300 to 12,000 cells/mm^3 (in the absence of clinical or pathological etiology)
  • Absolute neutrophil count (ANC) within the institutional normal ranges and greater than or equal to 1,000 cells/mm^3 or accompanied by site physician approval
  • Total lymphocyte count greater than 800 cells/mm^3
  • Platelets equal to 125,000 to 550,000 cells/mm^3
  • Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) less than 1.25 times the upper limit of normal (ULN)
  • Serum creatinine less than 1.0 times the ULN range
  • Normal urinalysis, defined as dipstick with negative glucose, negative or trace protein, and negative or trace hemoglobin (blood) or determined to be not clinically significant by site principal investigator
  • Negative serology for HIV infection (e.g., enzyme linked immunosorbent assay [ELISA] test, western blot [WB]) and HIV ribonucleic acid (RNA) below detection limits of Food and Drug Administration (FDA)-approved viral load diagnostic assay
  • Pregnancy-Specific Criteria:
  • Negative serum-human chorionic gonadotropin (HCG) pregnancy test for all women. A female participant must meet one of the following criteria from the screening visit and throughout the duration of the study:
  • No reproductive potential because of a hysterectomy, bilateral oophorectomy, or tubal ligation. Documentation from qualified medical doctor must be obtained for confirmation of procedure. OR
  • Participant agrees to consistently practice contraception at least 21 days prior to vaccination and throughout the duration of the study (13 months).
  • More information on this criterion can be found in the protocol

Who cannot join

  • Pregnant, breastfeeding, or planning to become pregnant during the period of study participation
  • Immunosuppressive or cytotoxic medications within the past 6 months with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis
  • Blood products within 120 days prior to HIV screening
  • Immunoglobulin within 60 days prior to HIV screening
  • Live attenuated vaccines within 30 days prior to initial study vaccine administration
  • Investigational research agents within 30 days prior to initial study vaccine administration
Show all 23Show fewer
  • Medically indicated subunit or killed vaccines, e.g., influenza, pneumococcal, or allergy treatment with antigen injections, within 14 days of study vaccine administration
  • Current anti-tuberculosis (TB) prophylaxis or therapy
  • People with a history of any of the following clinically significant conditions will be excluded:
  • Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  • Autoimmune disease or immunodeficiency
  • Asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years. Asthma that has required the use of oral or intravenous corticosteroids during the past 2 years.
  • Diabetes mellitus (type I or II), with the exception of gestational diabetes
  • Thyroid disease, including history of thyroidectomy and diagnoses that required medication within the past 36 months
  • Serious angioedema episodes within the previous 36 months or requiring medication in the previous 2 years
  • Hypertension that is not well controlled by medication or blood pressure greater than or equal to 150/100 mm Hg (either or both values) at second screening and/or entry visits
  • Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with intramuscular (IM) injections or blood draws
  • Active syphilis documented by exam or serology unless positive serology is because of remote treated infection or positive rapid plasma regain/venereal disease research laboratory (RPR/VDRL) test is not associated with positive Treponemal specific serology
  • Malignancy that is active, treated malignancy for which there is not reasonable assurance of sustained cure, or malignancy that is likely to recur during the period of the study
  • Seizure disorder other than febrile seizures under the age of 2
  • Asplenia or splenic hypoplasia (complete or partial lack of splenic function) or any condition resulting in the absence of a functional spleen or removal of the spleen
  • Psychiatric condition that precludes compliance with the protocol, past or present psychoses, past or present bipolar disorder, or suicidal attempts
  • Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence or a person's ability to give informed consent

Trial locations and contacts

1 site in 1 country.

Uganda1 site

  • Makerere University Walter Reed Project (MUWRP)

    Kampala

Other trials in Uganda

About this study

Official title: A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 Recombinant Adenovirus-5 Vector Vaccine, VRC-HIVADV014-00-VP Administered Alone or Administered as a Boost to a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, in Uninfected Adult Volunteers in Uganda

The RV 156A clinical trial is evaluating an experimental HIV vaccine in people who are not infected with HIV. Participants in that study are randomly assigned to receive either the HIV vaccine or placebo. This study will enroll people who are participating in the RV 156 study. In this study, researchers will evaluate the safety of and immune response to a different experimental HIV vaccine in people who participated in the RV 156 study.

Read the detailed description

RV 156A is a single site, phase 1 open label study with accrual restricted to participants in RV 156. Participants in the RV 156 study were randomly assigned to receive three injections of either placebo or the VRC-HIVDNA009-00-VP vaccine. All participants in this study will receive one injection of a different experimental HIV vaccine, VRC-HIVADV014-00-VP. The purpose of this study is to evaluate the safety and immunogenicity of the VRC-HIVADV014-00-VP vaccine in people who participated in the RV 156 study. Researchers will examine the differences in the immune response to the VRC-HIVADV014-00-VP vaccine between people who received placebo in the RV 156 study and people who received the VRC-HIVDNA009-00-VP vaccine in the RV 156 study.

A projected number of up to 29 volunteers will be enrolled from the Makerere University site in Uganda. At study entry, all participants will undergo a physical examination, medical history review, vital sign measurements, and blood and urine collection. They will also receive counseling for HIV prevention and pregnancy prevention. Participants will then receive one injection of the VRC-HIVADV014-00-VP vaccine in their upper arm. They will remain in the clinic for 30 to 45 minutes for observation and monitoring. For 3 days after the vaccination, participants will record their temperature and any adverse symptoms in a diary. Additional study visits will occur at Days 3, 14, 28, 42, 84, 168, 252, and 336. At each visit, participants will undergo the same study procedures that they completed at the study entry visit.

Conditions
HIV Infections
Being tested
VRC-HIVADV014-00-VP Vaccine
Medical subject headings
HIV Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VRC-HIVADV014-00-VP VaccineBiological

    All participants will receive one injection in their upper arm of 1 x 10^10 particle units (PU)/mL of VRC-HIVADV014-00-VP at study entry.

Study groups in NCT01549509
Study groupRoleWhat they receive
VRC-HIVADV014-00-VP VaccineExperimentalAll participants will receive one injection of the study vaccine (VRC-HIVADV014-00-VP) in their upper arm at study entry.
Receives: Biological: VRC-HIVADV014-00-VP Vaccine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Local reactogenicity signs and symptoms

    Measured: Measured through Day 336

  2. Systemic reactogenicity signs and symptoms

    Measured: Measured through Day 336

  3. Laboratory measures of safety

    Measured: Measured through Day 336

  4. Adverse and serious adverse experiences

    Measured: Measured through Day 336

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Mar 2012 (estimated)
  2. Study startApr 2007
  3. Primary completionApr 2008
  4. Study completionOct 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
18 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01549509
Sponsor's protocol ID
RV 156A
Other IDs
10469
Status last verified
Oct 2021
First submitted
6 Mar 2012
Last updated
1 Nov 2021
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing VRC-HIVADV014-00-VP Vaccine in people with HIV Infections, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in Uganda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 24 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Local reactogenicity signs and symptoms (time frame: Measured through Day 336). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01549509.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2021.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in